RT Journal Article
SR Electronic
A1 Angiolillo, Dominick
T1 BRIDGE Study Demonstrates Feasibility and Safety of Cangrelor
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 14
SP 10
OP 11
DO 10.1177/155989771114008
UL http://mdc.sagepub.com/content/11/14/10.abstract
AB Cangrelor is a rapid-acting, reversible, intravenous ADP-P2Y12 receptor antagonist with a plasma half-life of 3 to 6 minutes. The Maintenance of Platelet Inhibition With Cangrelor After Discontinuation of Thienopyridines in Patients Undergoing Surgery [BRIDGE; NCT00767507] study results evaluated the use of cangrelor for bridging thienopyridine-treated patients to coronary artery bypass graft.